2023
Study protocol for a randomized, controlled trial using a novel, family-centered diet treatment to prevent NAFLD in Hispanic children
Welsh J, Pyo E, Huneault H, Ramirez L, Alazraki A, Alli R, Dunbar S, Khanna G, Knight-Scott J, Pimentel A, Reed B, Rodney-Somersall C, Santoro N, Umpierrez G, Vos M. Study protocol for a randomized, controlled trial using a novel, family-centered diet treatment to prevent NAFLD in Hispanic children. Contemporary Clinical Trials 2023, 129: 107170. PMID: 37019180, PMCID: PMC10734403, DOI: 10.1016/j.cct.2023.107170.Peer-Reviewed Original ResearchConceptsNon-alcoholic fatty liver diseaseHispanic childrenFuture dietary guidelinesFatty liver diseasePrimary study outcomeLiver fat accumulationHigh-risk childrenSignificant hepatic steatosisOne-year interventionPercentile BMIElevated liverSecondary outcomesNAFLD preventionLiver diseaseLiver steatosisNAFLD pathogenesisPrevious diagnosisHepatic fatHepatic steatosisStudy protocolDietary guidelinesFat accumulationLiver disordersMetabolic markersEligibility criteria
2020
rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis
Teo K, Abeysekera KWM, Adams L, Aigner E, Anstee QM, Banales JM, Banerjee R, Basu P, Berg T, Bhatnagar P, Buch S, Canbay A, Caprio S, Chatterjee A, Chen Y, Chowdhury A, Daly AK, Datz C, de Gracia Hahn D, DiStefano JK, Dong J, Duret A, Investigators E, Vreugdenhil A, Alisi A, Socha P, Jańczyk W, Baumann U, Rajwal S, van Mourik I, Lacaille F, Dabbas M, Kelly D, Nobili V, Emdin C, Fairey M, Gerhard G, Consortium G, Eiriksdottir G, Garcia M, Gudnason V, Harris T, Kim L, Launer L, Nalls M, Smith A, Clark J, Hernaez R, Kao W, Mitchell B, Shuldiner A, Yerges-Armstrong L, Borecki I, Carr J, Feitosa M, Wu J, Butler J, Fox C, Hirschhorn J, Hoffmann U, Hwang S, Massaro J, O'Donnell C, Palmer C, Sahani D, Speliotes E, Guo X, Hampe J, Hickman M, Heintz L, Hudert C, Hunter H, Kelly M, Kozlitina J, Krawczyk M, Lammert F, Langenberg C, Lavine J, Li L, Lim H, Loomba R, Luukkonen P, Melton P, Mori T, Palmer N, Parisinos C, Pillai S, Qayyum F, Reichert M, Romeo S, Rotter J, Im Y, Santoro N, Schafmayer C, Speliotes E, Stender S, Stickel F, Still C, Strnad P, Taylor K, Tybjærg-Hansen A, Umano G, Utukuri M, Valenti L, Wagenknecht L, Wareham N, Watanabe R, Wattacheril J, Yaghootkar H, Yki-Järvinen H, Young K, Mann J. rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis. Journal Of Hepatology 2020, 74: 20-30. PMID: 32882372, PMCID: PMC7755037, DOI: 10.1016/j.jhep.2020.08.027.Peer-Reviewed Original ResearchConceptsFatty liver diseaseLiver diseaseAlanine aminotransferaseLiver fatRisk factorsSevere fatty liver diseaseCaucasian adultsHigh liver fatSpectrum of NAFLDDiagnosis of NAFLDSerum alanine aminotransferaseSeverity of NAFLDLower serum triglyceridesHigher alanine aminotransferaseCT/MRIDominant genetic modelRelated metabolic phenotypesGenome-wide association studiesPopulation-level dataNAFLD histologyAdvanced fibrosisLiver inflammationSerum triglyceridesHepatic fatAdvanced histology